Preface of the special issue on “A bespoke approach to rectal cancer resection and management”

Gordon N. Buchanan

Consultant Colorectal Surgeon, Lister Hospital, London SW1W 8RH, UK.

Correspondence to: Mr. Gordon Buchanan, Consultant Colorectal Surgeon, Lister Hospital, Chelsea Bridge Road, London SW1W 8RH, UK. E-mail: gordon.buchanan@hcaconsultant.co.uk

How to cite this article: Buchanan GN. Preface of the special issue on “A bespoke approach to rectal cancer resection and management”. Mini-invasive Surg 2019;3:8. http://dx.doi.org/10.20517/2574-1225.2019.24

Rectal cancer is increasingly managed by super-specialist colorectal and oncological teams - this has only become possible through the belief and drive of many key figures who often, despite lack of support from their peers, persevered in order to define the aspect of care they truly believed beneficial to improve outcomes. It is this collective work across decades that has enabled patients to have choice in scenarios that were often previously both bleak and debilitating. It is a great honour to act as guest editor for this special edition where many of these key international opinion leaders have generously contributed to help coalesce the goal for a bespoke approach to rectal cancer.

Tebala et al. [1] discuss the role of enhanced recovery and demonstrate how it can shorten stay and potentially reduce complications in this complex set of patients.

Chouhan et al. [2], with input both from the greatly experienced Korean and Australasian teams, have discussed in great depth the potential benefits of the robotic platform and even in early trials noted the trend to reduced conversion vs. laparoscopic resection in the obese male - as numbers grow this almost certainly will become more evident. They liken the robot to an open approach with its wrist movement but providing a more magnified view and the benefits of a minimally invasive surgery (MIS) approach. They provide some evidence that the robotic approach may improve survival potentially combined with better pathological outcomes; these benefits are further reviewed by Chen et al. [3] from Taiwan who found this technique safe in low lying rectal cancer.
Yellinek and Wexner⁴, writing from the Cleveland clinic, discuss an alternative to the robot, namely transanal total mesorectal excision (TaTME), the importance of a registry and training programme though concede that the single port robot may provide a method for better adopting this technique, potentially as a combined approach and ongoing trial data is awaited. De Nardi⁵ suggests that TaTME has comparable functional outcomes compared with the abdominal approach though the COLOR III trial results are eagerly awaited to assess this.

Ishida et al.⁶ recognise the difficulty associated with learning reduce port surgery, though again note that this technique once mastered may yield benefits in terms reduced operating time over single incision laparoscopic surgery, particularly with advancements in needlescopic surgery.

Ambe and Möslein⁷ discuss the role of extended resections in certain mutational and hereditary analyses, making the point that each case must be considered on its own merits after fully informed discussion with patients about the risks and benefits of each approach - this detailed piece provides an up to date review of most of the important hereditary and mutational conditions, how they are classified and defined as well as many operative illustrations pointing out the various surgical approaches possible.

Kumar⁸ looks beyond TME and the role of MIS surgery in exenterative surgery, pelvic lymphadenectomy and even abdomino-sacral resection.

Funahashi⁹ and colleagues outline their experience in Japanese patients of intersphincteric resection in low lying rectal cancer and how it can lead to organ preservation in many without compromising pathological outcomes - they notes the improved quality of life after preserving as much of the internal anal sphincter as possible.

O'Donohue et al.¹⁰ explore whether laparoscopic rectal surgery is non inferior, particularly assessing the COREAN, ALaCaRT and ACOSOG Z6051 trials. The concept of non-inferiority in the short term, vs. equivalent long term outcomes should not cloud the picture of the many advantages of an MIS approach, that are likely to be borne out with larger population based studies.

Westwood and West¹¹ emphasise how pathologists enhance feedback and thus quality of rectal cancer specimens and thus, patient outcomes. This quality control was largely the work of Quirke, coupled with imaging expertise from Brown G working with resection material generated via Heald in TME surgery - initially surgeons felt affronted by resections being graded though with importance on outcome, now entirely value the essential role of feeding this back via their multidisciplinary teams.

Erkan, Kelly and Monson¹² in Florida review the role of the transanal minimally invasive surgery (TAMIS) platform in locally resecting rectal cancer, particularly in T1 lesions or after chemo-radiotherapy and more controversially T2/4 lesions even in palliative scenarios - again Adegbola et al.¹³ from St Mark's, UK, additionally discuss the role of TAMIS with a robotic platform in exenterative surgery and other scenarios - i.e., trying to avoid major resectional surgery altogether.

Myint¹⁴ discusses the alternative of brachytherapy to radical resection and that patients with knowledge of this may reject MDT recommendations in favour of a more conservative approach - the OPERA database (organ preservation) will help provide useful outcome information in this regard.

All of these articles are well written and many beautifully illustrated, giving a concise appraisal of state of the art techniques. Some highlighted above do not take away all the other well-constructed opinion pieces that expand on the themes generated through principles of TME surgery and multidisciplinary input into this group of patients.
DECLARATIONS

Authors’ contributions
Buchanan GN contributed solely to this preface.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
The author declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES